I agree. I think a MASH licensing or partnership deal is in the works with preliminary discussions also started. What will close the deal are the follow-on studies expected to be released this month (January). That will make or break the deal. It's logical to me that a major MASH player may be very interested in Cytodyn current pre-clinical MASH data with confirmatory data on the way. A pilot study in patients is also anticipated if results are excellent.